Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MIST trial in preterm infants on CPAP
2013-005429-21Phase 4
- Sponsor
- Menzies Institute for Medical Research
- Start
- Jul 2015
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of Poractant alfa in respiratory distress syndrome (RDS) (2 arms), sponsored by Menzies Institute for Medical Research. Primary endpoint: Incidence of composite outcome of death or bronchopulmonary dysplasia.
02
Drugs
Poractant alfa
03
Conditions
respiratory distress syndrome (RDS)
Beyond the preview
Go deeper on 2013-005429-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-005429-21.